Literature DB >> 27979832

Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse.

Marco Demaria1,2, Monique N O'Leary3, Jianhui Chang4, Lijian Shao4, Su Liu3, Fatouma Alimirah3, Kristin Koenig3, Catherine Le3, Natalia Mitin5, Allison M Deal6, Shani Alston6, Emmeline C Academia3, Sumner Kilmarx3, Alexis Valdovinos3, Boshi Wang2, Alain de Bruin7,8, Brian K Kennedy3, Simon Melov3, Daohong Zhou4, Norman E Sharpless6, Hyman Muss6, Judith Campisi1,9.   

Abstract

Cellular senescence suppresses cancer by irreversibly arresting cell proliferation. Senescent cells acquire a proinflammatory senescence-associated secretory phenotype. Many genotoxic chemotherapies target proliferating cells nonspecifically, often with adverse reactions. In accord with prior work, we show that several chemotherapeutic drugs induce senescence of primary murine and human cells. Using a transgenic mouse that permits tracking and eliminating senescent cells, we show that therapy-induced senescent (TIS) cells persist and contribute to local and systemic inflammation. Eliminating TIS cells reduced several short- and long-term effects of the drugs, including bone marrow suppression, cardiac dysfunction, cancer recurrence, and physical activity and strength. Consistent with our findings in mice, the risk of chemotherapy-induced fatigue was significantly greater in humans with increased expression of a senescence marker in T cells prior to chemotherapy. These findings suggest that senescent cells can cause certain chemotherapy side effects, providing a new target to reduce the toxicity of anticancer treatments. SIGNIFICANCE: Many genotoxic chemotherapies have debilitating side effects and also induce cellular senescence in normal tissues. The senescent cells remain chronically present where they can promote local and systemic inflammation that causes or exacerbates many side effects of the chemotherapy. Cancer Discov; 7(2); 165-76. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 115. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27979832      PMCID: PMC5296251          DOI: 10.1158/2159-8290.CD-16-0241

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  33 in total

1.  Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer.

Authors:  Hanna K Sanoff; Allison M Deal; Janakiraman Krishnamurthy; Chad Torrice; Patrick Dillon; Jessica Sorrentino; Joseph G Ibrahim; Trevor A Jolly; Grant Williams; Lisa A Carey; Amy Drobish; Brittaney-Belle Gordon; Shani Alston; Arti Hurria; Karin Kleinhans; K Lenhard Rudolph; Norman E Sharpless; Hyman B Muss
Journal:  J Natl Cancer Inst       Date:  2014-03-28       Impact factor: 13.506

Review 2.  Senescence, apoptosis and therapy--cutting the lifelines of cancer.

Authors:  Clemens A Schmitt
Journal:  Nat Rev Cancer       Date:  2003-04       Impact factor: 60.716

Review 3.  Telomere dynamics in response to chemotherapy.

Authors:  N Beeharry; D Broccoli
Journal:  Curr Mol Med       Date:  2005-03       Impact factor: 2.222

4.  Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model.

Authors:  Christin E Burd; Jessica A Sorrentino; Kelly S Clark; David B Darr; Janakiraman Krishnamurthy; Allison M Deal; Nabeel Bardeesy; Diego H Castrillon; David H Beach; Norman E Sharpless
Journal:  Cell       Date:  2013-01-17       Impact factor: 41.582

Review 5.  Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all.

Authors:  R G van der Most; A J Currie; B W S Robinson; R A Lake
Journal:  Cell Death Differ       Date:  2007-11-16       Impact factor: 15.828

Review 6.  Systemic cancer therapy: evolution over the last 60 years.

Authors:  Grace K Dy; Alex A Adjei
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

7.  Clinical ascertainment of health outcomes among adults treated for childhood cancer.

Authors:  Melissa M Hudson; Kirsten K Ness; James G Gurney; Daniel A Mulrooney; Wassim Chemaitilly; Kevin R Krull; Daniel M Green; Gregory T Armstrong; Kerri A Nottage; Kendra E Jones; Charles A Sklar; Deo Kumar Srivastava; Leslie L Robison
Journal:  JAMA       Date:  2013-06-12       Impact factor: 56.272

8.  Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor.

Authors:  Jean-Philippe Coppé; Christopher K Patil; Francis Rodier; Yu Sun; Denise P Muñoz; Joshua Goldstein; Peter S Nelson; Pierre-Yves Desprez; Judith Campisi
Journal:  PLoS Biol       Date:  2008-12-02       Impact factor: 8.029

9.  p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes.

Authors:  Albert R Davalos; Misako Kawahara; Gautam K Malhotra; Nicholas Schaum; Jiahao Huang; Urvi Ved; Christian M Beausejour; Jean-Philippe Coppe; Francis Rodier; Judith Campisi
Journal:  J Cell Biol       Date:  2013-05-06       Impact factor: 10.539

10.  Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan.

Authors:  Darren J Baker; Bennett G Childs; Matej Durik; Melinde E Wijers; Cynthia J Sieben; Jian Zhong; Rachel A Saltness; Karthik B Jeganathan; Grace Casaclang Verzosa; Abdulmohammad Pezeshki; Khashayarsha Khazaie; Jordan D Miller; Jan M van Deursen
Journal:  Nature       Date:  2016-02-03       Impact factor: 49.962

View more
  332 in total

1.  Structural Refinement of the Tubulin Ligand (+)-Discodermolide to Attenuate Chemotherapy-Mediated Senescence.

Authors:  Boying Guo; Alicia Rodriguez-Gabin; Andrea E Prota; Tobias Mühlethaler; Nan Zhang; Kenny Ye; Michel O Steinmetz; Susan Band Horwitz; Amos B Smith; Hayley M McDaid
Journal:  Mol Pharmacol       Date:  2020-06-26       Impact factor: 4.436

2.  HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.

Authors:  Simona di Martino; Carla Azzurra Amoreo; Barbara Nuvoli; Rossella Galati; Sabrina Strano; Francesco Facciolo; Gabriele Alessandrini; Harvey I Pass; Gennaro Ciliberto; Giovanni Blandino; Ruggero De Maria; Mario Cioce
Journal:  Oncogene       Date:  2018-01-09       Impact factor: 9.867

Review 3.  CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.

Authors:  Mary E Klein; Marta Kovatcheva; Lara E Davis; William D Tap; Andrew Koff
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

4.  Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence.

Authors:  Prashanth K B Nagesh; Pallabita Chowdhury; Elham Hatami; Sonam Kumari; Vivek Kumar Kashyap; Manish K Tripathi; Santosh Wagh; Bernd Meibohm; Subhash C Chauhan; Meena Jaggi; Murali M Yallapu
Journal:  ACS Appl Mater Interfaces       Date:  2019-10-08       Impact factor: 9.229

Review 5.  Senescent cells: an emerging target for diseases of ageing.

Authors:  Bennett G Childs; Martina Gluscevic; Darren J Baker; Remi-Martin Laberge; Dan Marquess; Jamie Dananberg; Jan M van Deursen
Journal:  Nat Rev Drug Discov       Date:  2017-07-21       Impact factor: 84.694

Review 6.  The role of neuro-immune interactions in cancer-related fatigue: Biobehavioral risk factors and mechanisms.

Authors:  Julienne E Bower
Journal:  Cancer       Date:  2019-01-02       Impact factor: 6.860

Review 7.  Mechanisms of Normal Tissue Injury From Irradiation.

Authors:  Deborah E Citrin; James B Mitchell
Journal:  Semin Radiat Oncol       Date:  2017-10       Impact factor: 5.934

8.  Contrasting characteristics of daily physical activity in older adults by cancer history.

Authors:  Amal A Wanigatunga; Gillian K Gresham; Pei-Lun Kuo; Pablo Martinez-Amezcua; Vadim Zipunnikov; Sydney M Dy; Eleanor M Simonsick; Luigi Ferrucci; Jennifer A Schrack
Journal:  Cancer       Date:  2018-10-01       Impact factor: 6.860

9.  Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.

Authors:  Sylvia S Gayle; Jennifer M Sahni; Bryan M Webb; Kristen L Weber-Bonk; Melyssa S Shively; Raffaella Spina; Eli E Bar; Mathew K Summers; Ruth A Keri
Journal:  J Biol Chem       Date:  2018-11-27       Impact factor: 5.157

10.  Remodeling of the H3 nucleosomal landscape during mouse aging.

Authors:  Yilin Chen; Juan I Bravo; Jyung Mean Son; Changhan Lee; Bérénice A Benayoun
Journal:  Transl Med Aging       Date:  2020-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.